First “Follow-On Biologic” Insulin in US Set to Grab Significant Market Share in Basal Insulin Space

  • RSS Feed

Eli Lilly and Boehringer Ingelheim (BI) have recently announced the launch of the first follow-on biologic insulin, Basaglar (insulin glargine), in the US. Basaglar is a biologic copy, or biosimilar, of Sanofi’s Lantus (insulin glargine), a basal insulin analog used in diabetes patients, giving a long duration of action allowing for once-daily injection. Lantus is the world's best-selling insulin brand in terms of both sales and units; however, Lantus’ patents have recently expired and in anticipation of the expiration, Eli Lilly has received approval for Basaglar and has subsequently launched Basaglar in Europe, Japan, and the US. In the US, Basaglar faced a patent infringement lawsuit filed by Sanofi.

Gain full access to this article

You must register to read the full Expert Insight article. Register for FREE today and access all our healthcare Expert Insights.

Register

Registering for our Expert Insights is free and only takes a moment.

Following this you'll gain unlimited access to all of the latest, event-driven opinion put together by our teams of experienced analysts.

Send to a colleague

×
 
 
 

© GlobalData 2017. John Carpenter House, 7 Carmelite Street, London EC4 0BS.